U.S. Hospitality Stock News

NasdaqGM:MOB
NasdaqGM:MOBCommunications

Taking Stock of Mobilicom (NasdaqCM:MOB)’s Valuation After Its Recent Share Price Strength

Mobilicom (MOB) has quietly turned into one of the stronger performers in defense-tech, with the stock up about 13% over the past day and roughly 21% over the past month. See our latest analysis for Mobilicom. That jump in the latest share price to $7.975, on top of a hefty year to date share price return, suggests investors are steadily repricing Mobilicom for higher growth and possibly lower perceived risk. Momentum appears to be building rather than fading. If Mobilicom’s run has you...
NYSE:BLND
NYSE:BLNDSoftware

Blend Labs (BLND) Is Up 7.4% After Doubling Down On AI Mortgage Automation And Home Equity Plans

In early December 2025, Blend Labs outlined at the Wells Fargo 9th Annual TMT Summit how it is concentrating on core software, integrating AI to speed up mortgage processing, and expanding its Rapid Suite, following a shift away from non-core operations and a move to non-GAAP operating profitability. The company also revealed plans for its new Rapid Home Equity product, which it expects will significantly increase revenue earned per loan unit, while recent insider share purchases and...
NYSE:AZO
NYSE:AZOSpecialty Retail

AutoZone (AZO) Q1 2026 Margin Compression Challenges Bullish Earnings Growth Narratives

AutoZone (AZO) opened fiscal Q1 2026 with total revenue of $4.6 billion and basic EPS of $31.88, setting the stage against a backdrop where trailing twelve month revenue sits at $19.3 billion and EPS at $147.34. Over recent quarters the company has seen revenue move from $6.2 billion in Q4 2024 to $6.2 billion in Q4 2025 and then to $4.6 billion in Q1 2026, while quarterly EPS tracked from $53.0 to $50.0 and now $31.9, leaving investors weighing solid top line scale against signs of...
NasdaqGM:FULC
NasdaqGM:FULCPharmaceuticals

Fulcrum Therapeutics (FULC): Valuation Check After PIONEER Trial Success and Follow-On Offering

Fulcrum Therapeutics (FULC) has just delivered early PIONEER trial data that moved the needle, with pociredir driving meaningful fetal hemoglobin gains in sickle cell patients and setting up the stock for a very different conversation. See our latest analysis for Fulcrum Therapeutics. The PIONEER update has clearly reset expectations. Fulcrum’s 1 day share price return of 45.96% has helped drive a 30 day share price return of 70.25% and a 1 year total shareholder return of 223.94%, suggesting...
NasdaqGS:SRAD
NasdaqGS:SRADHospitality

3 Stocks Estimated To Be Undervalued In December 2025

As the Federal Reserve meeting unfolds and major indices like the Dow Jones, S&P 500, and Nasdaq show modest gains, investors are keenly observing how potential interest rate cuts might influence market dynamics. In this environment of cautious optimism and strategic shifts, identifying undervalued stocks becomes crucial for those looking to capitalize on potential market inefficiencies.